Education
About Us
Working with TipRanks
Follow Us
Viatris (DE:VIA)
XETRA:VIA
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.48Last Year’s EPS
0.6Same Quarter Last Year
Moderate Sell
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 3.15%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed outlook. While there are significant advancements in the pipeline and strong performance in specific regions like Europe and China, challenges such as the revenue decline due to the Indore facility impact, a substantial goodwill impairment charge, and potential tariff-related issues pose significant hurdles.Company Guidance
In the Viatris Q1 2025 earnings call, the company provided guidance indicating a solid start to the fiscal year with Q1 revenues totaling $3.3 billion, reflecting a 2% decrease on a divestiture-adjusted operational basis. Notable achievements included returning approximately $450 million to shareholders, with $300 million through share repurchases, and announcing positive Phase 3 data for three drugs. These included a novel fast-acting meloxicam for acute pain, XULANE LO for birth control, and EFFEXOR for generalized anxiety disorder in Japan. The company reaffirmed its commitment to returning capital to shareholders and maintained its financial outlook for 2025, expecting revenue growth in the latter half of the year and new product revenues between $450 million and $550 million. Despite challenges such as potential tariffs and ongoing remediation at the Indore facility, Viatris remains optimistic about future growth, with strategic focus on pipeline advancement and operational excellence.Significant Pipeline Progress
Three positive Phase 3 data readouts, including novel fast-acting meloxicam for acute pain and XULANE LO transdermal patch for birth control, with plans for regulatory submissions in 2025.
Capital Return to Shareholders
Returned approximately $450 million in capital to shareholders, including $300 million through share repurchases and $143 million from dividends.
Strong Performance in Europe and China
Growth in Europe and China contributed positively to overall performance, with 4% growth in China driven by a diversified model across e-commerce, retail, and private hospitals.
Positive Developments in R&D
Strong momentum in advancing Phase 3 programs, with promising results in pain management and women's health.
DE:VIA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:VIA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | €7.51 | €8.18 | +8.89% |
Feb 27, 2025 | €10.53 | €8.79 | -16.49% |
Nov 07, 2024 | €10.58 | €11.63 | +9.98% |
Aug 08, 2024 | €9.96 | €10.99 | +10.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Viatris (DE:VIA) report earnings?
Viatris (DE:VIA) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Viatris (DE:VIA) earnings time?
Viatris (DE:VIA) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Viatris stock?
The P/E ratio of Viatris is N/A.
What is DE:VIA EPS forecast?
DE:VIA EPS forecast for the fiscal quarter 2025 (Q2) is 0.48.
